Otsuka: Pipeline, Products, Performance, Potential

Table of Contents

EXECUTIVE SUMMARY

• Introduction
• Financial performance 2005
  • Sales and Market Position
  • Income
    • Sales, Costs and Operating Income
  • Expenditure
    • Capital Expenditure
  • Divisional Performance
    • Global Sales by Business Area
    • Global Sales by Business Area
    • Total Assets by Business Area
  • Geographic Performance
    • Sales by Destination
    • Sales by Destination
    • Sales by Origin
    • Sales by Origin
• Company strategy
  • Mergers, Acquisitions and Divestitures
  • Production
  • Employees
  • Key Agreements
• Product/R&D overview
  • Key Products
    • Recent Product Launches
    • Recent Product Approvals
  • R&D Strategy
    • Key R&D Projects
• Conclusions

PRODUCT PORTFOLIO/RESEARCH & DEVELOPMENT

• R&D Pipeline
• Respiratory - Products
  • Major Launched Products
  • IPD-1151T
    • Key Markets/Indications
    • Further Development
  • Meptin
    • Key Markets/Indications/Formulations
    • Competitor Products
  • Synaclyn
  • UNIPHYL
    • Key Markets
• Respiratory - summary
• Cardiovascular - Products
  • Major Launched Products
  • Arkin-Z
    • Mode of Action
    • Key Markets/Indications/Formulations
  • Hi-Z
    • Key Markets/Indications/Formulations
  • Lorelco
    • Mode of Action
    • Key Markets/Indications
  • Mikelan
    • Key Markets/Indications/Formulations
    • Further Development
  • Pleetal/Pletal
    • Mode of Action
    • Key Markets/Indications/Formulations
    • Further Development
    • Competitor Products
    • Generic Competition
    • Clinical Trial Results
  • Sapresta/Bec
• Cardiovascular - R&D
  • Acalas
  • OPC-28326
  • Toborinone
  • Tolvaptan
• Cardiovascular - Summary
  • Growth Potential
  • Limiting Factors
• Gastrointestinal - Products
  • Mucosta
    • Mode of Action
    • Key Markets/Indications/Formulations
    • Licensees
• Central Nervous System - Products
  • Abilify
    • Mode of Action
    • Key Markets/Indications/Formulations
    • Competitor Products
    • Safety Issues
    • Clinical Trial Results
  • Myocalm
• Central Nervous System - R&D
  • OPC-14523
  • Rotigotine CDS
• Central Nervous System - Summary
  • Growth Potential
  • Limiting Factors
• Dermatology - Products
  • Acuatim
    • Mode of Action
    • Key Markets/Indications/Formulations
  • Urepearl
    • Mode of action
    • Key Markets/Indications/Formulations
• Dermatology - SUMMARY
• Anticancer - Products
  • Abraxane
    • Clinical Trial Results
  • Futraful
  • Lentinan
  • O-gamma 100
  • OIF
    • Mode of Action
    • Key Markets/Indications/Formulations
  • S-1 (TS-1)
    • Mode of Action
    • Key Markets/Indications/Formulations
    • Further Development
  • Stogar
  • UFT
    • Key Markets/Indications
• Anticancer - R&D
  • Last-F
  • TAS-108
• Anticancer - Summary
  • Growth Potential
• Anti-infective - Products
  • Herzer
  • Kenicef
  • Meropen
    • Mode of Action
    • Licensees
  • Miridacin
  • Otsuka CEZ Injection-MC
  • Palavale
• Anti-infective - R&D
  • OPC-2045
  • TN-3262a
• Anti-infective - Summary
• Others - Products
  • Aminoleban/Aminoleban EN/Kidmin
  • BUP-4
  • FerriSeltz
  • Lepetan
  • Neophagen
  • Solcoseryl Injection
    • Licensee
  • Others
• OTHERS - R&D
  • OPC-51803
  • OPC-6535
  • Vitrase
• Others - Summary

APPENDIX 1 - FINANCIAL PERFORMANCE

• Full year results 2005
  • Sales, Costs and Operating Income
  • Operating Margin (%)
  • Capital Expenditure
  • Current Assets, Liabilities and Ratio
  • Assets, Cash and Liquidity
  • Employees and Productivity

APPENDIX 2 - KEY CORPORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

• Abraxis Bioscience Inc
  • November 2005
• Astellas Pharma Inc
  • 23rd January 2003
• Bristol-Myers Squibb
  • Oncology agreements
  • 17th April 1995
  • 6th August 1997
  • Aripiprazole Agreement
  • 20th September 1999
• Galenea Corporation
  • 17th February 2005
• GlaxoSmithKline
  • 25th July 2000
• Innovata Biomed Limited
  • 20th March 2003
  • 5th May 2004
• ISTA Pharmaceuticals Inc
  • 20th December 2001
• Merck KGaA
  • 14th July 2005
• Methylgene Inc
  • October 2003
• Novartis Ophthalmics
  • 12th January 1999
  • 7th February 2005
• Pfizer
  • 30th July 1998
  • 28th April 1999
• Prasco Laboratories
  • 18th October 2004
• Schwarz Pharma AG
  • 14th November 2002
• Sosei Co Ltd
  • 22nd February 2005
• SRI International
  • 8th June 1999
• Toyama Chemical Co Ltd/Nidek Co Ltd
  • 18th March 2003
• Vela Pharmaceuticals Inc
  • 1st April 2004
• Others

APPENDIX 4 - INFRASTRUCTURE

• Research and development facilities
• Manufacturing facilities

APPENDIX 5 - MAJOR PHARMACEUTICAL

SUBSIDIARIES/JOINT VENTURES

• Subsidiaries
• Joint-venture Companies

APPENDIX 6 - PRODUCT INDEX